Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Economic evaluation of propofol and lorazepam for critically ill patients undergoing mechanical ventilation.

Publication ,  Journal Article
Cox, CE; Reed, SD; Govert, JA; Rodgers, JE; Campbell-Bright, S; Kress, JP; Carson, SS
Published in: Crit Care Med
March 2008

OBJECTIVE: The economic implications of sedative choice in the management of patients receiving mechanical ventilation are unclear because of differences in costs and clinical outcomes associated with specific sedatives. Therefore, we aimed to determine the cost-effectiveness of the most commonly used sedatives prescribed for mechanically ventilated critically ill patients. DESIGN, SETTING, AND PATIENTS: Adopting the perspective of a hospital, we developed a probabilistic decision model to determine whether continuous propofol or intermittent lorazepam was associated with greater value when combined with daily awakenings. We also evaluated the comparative value of continuous midazolam in secondary analyses. We assumed that patients were managed in a medical intensive care unit and expected to require ventilation for > or = 48 hrs. Model inputs were derived from primary analysis of randomized controlled trial data, medical literature, Medicare reimbursement rates, pharmacy databases, and institutional data. MAIN RESULTS: We measured cost-effectiveness as costs per mechanical ventilator-free day within the first 28 days after intubation. Our base-case probabilistic analysis demonstrated that propofol dominated lorazepam in 91% of simulations and, on average, was both $6,378 less costly per patient and associated with more than three additional mechanical ventilator-free days. The model did not reveal clinically meaningful differences between propofol and midazolam on costs or measures of effectiveness. CONCLUSION: Propofol has superior value compared with lorazepam when used for sedation among the critically ill who require mechanical ventilation when used in the setting of daily sedative interruption.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Crit Care Med

DOI

EISSN

1530-0293

Publication Date

March 2008

Volume

36

Issue

3

Start / End Page

706 / 714

Location

United States

Related Subject Headings

  • Respiration, Artificial
  • Propofol
  • Middle Aged
  • Lorazepam
  • Hypnotics and Sedatives
  • Humans
  • Emergency & Critical Care Medicine
  • Decision Trees
  • Critical Illness
  • Cost-Benefit Analysis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cox, C. E., Reed, S. D., Govert, J. A., Rodgers, J. E., Campbell-Bright, S., Kress, J. P., & Carson, S. S. (2008). Economic evaluation of propofol and lorazepam for critically ill patients undergoing mechanical ventilation. Crit Care Med, 36(3), 706–714. https://doi.org/10.1097/CCM.0B013E3181544248
Cox, Christopher E., Shelby D. Reed, Joseph A. Govert, Jo E. Rodgers, Stacy Campbell-Bright, John P. Kress, and Shannon S. Carson. “Economic evaluation of propofol and lorazepam for critically ill patients undergoing mechanical ventilation.Crit Care Med 36, no. 3 (March 2008): 706–14. https://doi.org/10.1097/CCM.0B013E3181544248.
Cox CE, Reed SD, Govert JA, Rodgers JE, Campbell-Bright S, Kress JP, et al. Economic evaluation of propofol and lorazepam for critically ill patients undergoing mechanical ventilation. Crit Care Med. 2008 Mar;36(3):706–14.
Cox, Christopher E., et al. “Economic evaluation of propofol and lorazepam for critically ill patients undergoing mechanical ventilation.Crit Care Med, vol. 36, no. 3, Mar. 2008, pp. 706–14. Pubmed, doi:10.1097/CCM.0B013E3181544248.
Cox CE, Reed SD, Govert JA, Rodgers JE, Campbell-Bright S, Kress JP, Carson SS. Economic evaluation of propofol and lorazepam for critically ill patients undergoing mechanical ventilation. Crit Care Med. 2008 Mar;36(3):706–714.

Published In

Crit Care Med

DOI

EISSN

1530-0293

Publication Date

March 2008

Volume

36

Issue

3

Start / End Page

706 / 714

Location

United States

Related Subject Headings

  • Respiration, Artificial
  • Propofol
  • Middle Aged
  • Lorazepam
  • Hypnotics and Sedatives
  • Humans
  • Emergency & Critical Care Medicine
  • Decision Trees
  • Critical Illness
  • Cost-Benefit Analysis